Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis

Introduction: Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and prognosis. Methods: We compared serum microRNA (miRNA) expression from patients with ALS with healthy controls and patients with multiple sclerosis and Alzheimer disease. We also correlated miRNA expression in cross‐sectional and longitudinal cohorts of ALS patients with clinical parameters. Results: We identified 7 miRNAs (miR‐192‐5p, miR‐192‐3p, miR‐1, miR‐133a‐3p, miR‐133b, miR‐144‐5p, miR‐19a‐3p) that were upregulated and 6 miRNAs (miR‐320c, miR‐320a, let‐7d‐3p, miR‐425‐5p, miR‐320b, miR‐139‐5p) that were downregulated in patients with ALS compared with healthy controls, patients with Alzheimer disease, and patients with multiple sclerosis. Changes in 4 miRNAs (miR‐136‐3p, miR‐30b‐5p, miR‐331‐3p, miR‐496) correlated positively and change in 1 miRNA (miR‐2110) correlated negatively with changes in clinical parameters in longitudinal analysis. Discussion: Our findings identified serum miRNAs that can serve as biomarkers for ALS diagnosis and progression. Muscle Nerve 58: 261–269, 2018

[1]  Y. Itoyama,et al.  Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial , 2017, The Lancet Neurology.

[2]  Ashish Ranjan Sharma,et al.  Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine , 2017, Molecular therapy. Nucleic acids.

[3]  O. Hermine,et al.  ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? , 2017, Front. Aging Neurosci..

[4]  F. Slack,et al.  MicroRNA therapeutics: towards a new era for the management of cancer and other diseases , 2017, Nature Reviews Drug Discovery.

[5]  Dongqing Wei,et al.  Gene expression profiles and protein-protein interaction networks in amyotrophic lateral sclerosis patients with C9orf72 mutation , 2016, Orphanet Journal of Rare Diseases.

[6]  L. Wilkins.  Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[7]  H. Shang,et al.  Aberration of miRNAs Expression in Leukocytes from Sporadic Amyotrophic Lateral Sclerosis , 2016, Front. Mol. Neurosci..

[8]  Keith A. Johnson,et al.  Trans-pQTL study identifies immune crosstalk between Parkinson and Alzheimer loci , 2016, Neurology: Genetics.

[9]  U. Frandsen,et al.  Skeletal Muscle Remodelling as a Function of Disease Progression in Amyotrophic Lateral Sclerosis , 2016, BioMed research international.

[10]  J. Hur,et al.  Expression of microRNAs in human post-mortem amyotrophic lateral sclerosis spinal cords provides insight into disease mechanisms , 2016, Molecular and Cellular Neuroscience.

[11]  V. Rani,et al.  Exploring miRNA based approaches in cancer diagnostics and therapeutics. , 2016, Critical reviews in oncology/hematology.

[12]  Subrata Sen,et al.  MicroRNA as Biomarkers and Diagnostics , 2016, Journal of cellular physiology.

[13]  Artemis G. Hatzigeorgiou,et al.  DIANA-miRPath v3.0: deciphering microRNA function with experimental support , 2015, Nucleic Acids Res..

[14]  B. Traynor,et al.  Genetic causes of amyotrophic lateral sclerosis: New genetic analysis methodologies entailing new opportunities and challenges , 2015, Brain Research.

[15]  Stephen A. Goutman,et al.  Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era , 2015, Nature Reviews Neurology.

[16]  C. O'Connell,et al.  MicroRNAs as Potential Circulating Biomarkers for Amyotrophic Lateral Sclerosis , 2015, Journal of Molecular Neuroscience.

[17]  H. Mitsumoto,et al.  Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? , 2014, The Lancet Neurology.

[18]  S. Luo,et al.  Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study , 2014, Nature Methods.

[19]  J. Broach,et al.  Genetic heterogeneity of amyotrophic lateral sclerosis: Implications for clinical practice and research , 2014, Muscle & nerve.

[20]  M. Denti,et al.  Circulating miRNAs as Biomarkers for Neurodegenerative Disorders , 2014, Molecules.

[21]  P. Sanberg,et al.  Blood-CNS Barrier Impairment in ALS patients versus an animal model , 2014, Front. Cell. Neurosci..

[22]  Adriano Chiò,et al.  State of play in amyotrophic lateral sclerosis genetics , 2013, Nature Neuroscience.

[23]  G. Chadi,et al.  Early gene expression changes in spinal cord from SOD1G93A Amyotrophic Lateral Sclerosis animal model , 2013, Front. Cell. Neurosci..

[24]  A. Al-Chalabi,et al.  The epidemiology of ALS: a conspiracy of genes, environment and time , 2013, Nature Reviews Neurology.

[25]  Timothy A. Miller,et al.  Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice. , 2013, Human molecular genetics.

[26]  A. Ludolph,et al.  Systemic dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis , 2013, Acta neuropathologica communications.

[27]  A. McKee,et al.  MST1 functions as a key modulator of neurodegeneration in a mouse model of ALS , 2013, Proceedings of the National Academy of Sciences.

[28]  R. Myers,et al.  Intricate interplay between astrocytes and motor neurons in ALS , 2013, Proceedings of the National Academy of Sciences.

[29]  I. Bozzoni,et al.  FUS stimulates microRNA biogenesis by facilitating co‐transcriptional Drosha recruitment , 2012, The EMBO journal.

[30]  R. Spataro,et al.  Factors affecting the diagnostic delay in amyotrophic lateral sclerosis , 2012, Clinical Neurology and Neurosurgery.

[31]  Y. Kawahara,et al.  TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes , 2012, Proceedings of the National Academy of Sciences.

[32]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[33]  T. Callis,et al.  MicroRNAs 1, 133, and 206: critical factors of skeletal and cardiac muscle development, function, and disease. , 2010, The international journal of biochemistry & cell biology.

[34]  D. Karolina,et al.  MicroRNA 320a Functions as a Novel Endogenous Modulator of Aquaporins 1 and 4 as Well as a Potential Therapeutic Target in Cerebral Ischemia* , 2010, The Journal of Biological Chemistry.

[35]  John McAnally,et al.  MicroRNA-206 Delays ALS Progression and Promotes Regeneration of Neuromuscular Synapses in Mice , 2009, Science.

[36]  V. Kim,et al.  Regulation of microRNA biogenesis , 2014, Nature Reviews Molecular Cell Biology.

[37]  R. Trent,et al.  A genome-wide analysis of brain DNA methylation identifies new candidate genes for sporadic amyotrophic lateral sclerosis , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[38]  P. Leigh,et al.  Prevalence of depression in a 12‐month consecutive sample of patients with ALS , 2007, European journal of neurology.

[39]  Jian-Fu Chen,et al.  The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation , 2006, Nature Genetics.

[40]  S H Appel,et al.  Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[41]  J. Cano,et al.  Blood–brain barrier disruption highly induces aquaporin‐4 mRNA and protein in perivascular and parenchymal astrocytes: Protective effect by estradiol treatment in ovariectomized animals , 2005, Journal of neuroscience research.

[42]  Claus Lindbjerg Andersen,et al.  Normalization of Real-Time Quantitative Reverse Transcription-PCR Data: A Model-Based Variance Estimation Approach to Identify Genes Suited for Normalization, Applied to Bladder and Colon Cancer Data Sets , 2004, Cancer Research.

[43]  J. Cedarbaum,et al.  The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function , 1999, Journal of the Neurological Sciences.

[44]  B. Brooks,et al.  El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis , 1994, Journal of the Neurological Sciences.

[45]  V. Meininger,et al.  A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. , 1994, The New England journal of medicine.

[46]  C. Angelini,et al.  Circulating microRNAs as biomarkers of muscle differentiation and atrophy in ALS. , 2016, Clinical neuropathology.

[47]  E. Granucci.  Evaluating the role of the Hippo pathway in the onset and disease progression of the SOD1 mouse model of Amyotrophic Lateral Sclerosis , 2016 .